Spot urine is a suitable matrix for measurement of copeptin
-
Julie Sherfan
,
Sonya Franke
Abstract
Objectives
To validate urine as a suitable matrix for copeptin measurements, derive a urinary copeptin/creatinine ratio in an apparently healthy sample of the population, and assess pre-analytical conditions such as collection type and storage temperatures that affect stability and recovery.
Methods
Matrix effect was determined by spiking the manufacturer’s calibrator F simultaneously into pooled serum and aliquots of spot urine sample donated by a single volunteer. Stability was assessed without preservatives as well as 0.0032×g of thymol or 1 mL of 5 M hydrochloric acid. The urinary copeptin-to-creatinine ratio reference limit was derived from random spot urines collected from 120 apparently healthy volunteers who met the selection criteria.
Results
Our in-house derived urinary copeptin-to-creatinine ratio was<2.5 pmol/mmol creatinine, and there was a statistically significant difference in urinary copeptin concentration between males and females, but this was eliminated when corrected for urine creatinine. 24-h and spot urine with and without preservatives were stable for 7 days at 4–8 °C, 23–25 °C, and −20 °C. Limits of blank, limits of detection, and limit of quantitation were 1.1 pmol/L, and 1.81 pmol/L, respectively.
Conclusions
Urine matrix does not distort the kinetics of the BRAHMS Thermo Fisher Copeptin assay and therefore could be measured with high accuracy. The clinical utility of urinary copeptin is still unknown, however, there is growing interest in this area in patient with autosomal polycystic kidney disease.
Acknowledgments
We’d like to acknowledge A/Prof Tony Badrick from the Royal College of Pathologist of Australasia Quality Assurance Program (RCPA QAP) for his valuable input in reviewing the manuscript and providing constructive feedback.
-
Research ethics: The study was approved by the Sydney Local Health District Ethics Committee at Royal Prince Alfred Hospital (X18-0127 & HREC/18/RPAH/174).
-
Informed consent: Informed consent was obtained from all individuals included in this study, or their legal guardians or wards.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Use of Large Language Models, AI and Machine Learning Tools: ProWriting Aid used to correct grammatical errors.
-
Conflict of interest: The authors state no conflict of interest.
-
Research funding: None declared.
-
Data availability: Not applicable.
References
1. De Bree, F, Burbach, J. Structure–function relationships of the vasopressin prohormone domains. Cell Mol Neurobiol 1998;18:173–91. https://doi.org/10.1023/a:1022564803093.10.1023/A:1022564803093Search in Google Scholar
2. Robertson, GL, Shelton, RL, Athar, S. The osmoregulation of vasopressin. Kidney Int 1976;10:25–37. https://doi.org/10.1038/ki.1976.76.Search in Google Scholar PubMed
3. Fahrenholz, F, Boer, R, Crause, P, Toth, MV. Photoaffinity labelling of the renal V2 vasopressin receptor: identification and enrichment of a vasopressin‐binding subunit. Eur J Biochem 1985;152:589–95. https://doi.org/10.1111/j.1432-1033.1985.tb09236.x.Search in Google Scholar PubMed
4. Keegan, BP, Memoli, VA, Wells, WA, North, WG. Detection of provasopressin in invasive and non-invasive (DCIS) human breast cancer using a monoclonal antibody directed against the C-terminus (MAG1). Breast Cancer Basic Clin Res 2010;4:117822341000400002. https://doi.org/10.1177/117822341000400002.Search in Google Scholar
5. Fenske, W, Stork, S, Blechschmidt, A, Maier, SG, Morgenthaler, NG, Allolio, B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metabol 2009;94:123–9. https://doi.org/10.1210/jc.2008-1426.Search in Google Scholar PubMed
6. Fenske, W, Lorenz, D, Haagen, U, Papassotiriou, J, Fassnacht, M, Quinkler, M, et al.. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome–revisiting the direct and indirect water deprivation tests. Exp Clin Endocrinol Diabetes 2010;118:P27. https://doi.org/10.1055/s-0030-1267029.Search in Google Scholar
7. Keller, T, Tzikas, S, Zeller, T, Czyz, E, Lillpopp, L, Ojeda, FM, et al.. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010;55:2096–106. https://doi.org/10.1016/j.jacc.2010.01.029.Search in Google Scholar PubMed
8. Maisel, A, Mueller, C, Neath, S-X, Christenson, RH, Morgenthaler, NG, McCord, J, et al.. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (copeptin helps in the early detection of patients with acute myocardial INfarction). J Am Coll Cardiol 2013;62:150–60. https://doi.org/10.1016/j.jacc.2013.04.011.Search in Google Scholar PubMed
9. Morawiec, B, Kawecki, D. Copeptin: a new marker in cardiology. J Cardiovasc Med 2013;14:19–25. https://doi.org/10.2459/jcm.0b013e3283590d59.Search in Google Scholar PubMed
10. Christ-Crain, M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010;140:w13101. https://doi.org/10.4414/smw.2010.13101.Search in Google Scholar PubMed
11. De Marchis, GM, Katan, M, Weck, A, Fluri, F, Foerch, C, Findling, O, et al.. Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study. Neurology 2013;80:1278–86. https://doi.org/10.1212/wnl.0b013e3182887944.Search in Google Scholar
12. Urwyler, SA, Schuetz, P, Fluri, F, Morgenthaler, NG, Zweifel, C, Bergmann, A, et al.. Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke 2010;41:1564–7. https://doi.org/10.1161/strokeaha.110.584649.Search in Google Scholar
13. Müller, B, Morgenthaler, N, Stolz, D, Schuetz, P, Müller, C, Bingisser, R, et al.. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007;37:145–52. https://doi.org/10.1111/j.1365-2362.2007.01762.x.Search in Google Scholar PubMed
14. Gansevoort, RT, van Gastel, MD, Chapman, AB, Blais, JD, Czerwiec, FS, Higashihara, E, et al.. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int 2019;96:159–69. https://doi.org/10.1016/j.kint.2018.11.044.Search in Google Scholar PubMed PubMed Central
15. Boertien, WE, Meijer, E, Li, J, Bost, JE, Struck, J, Flessner, MF, et al.. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis 2013;61:420–9. https://doi.org/10.1053/j.ajkd.2012.08.038.Search in Google Scholar PubMed PubMed Central
16. Zittema, D, van den Berg, E, Meijer, E, Boertien, WE, Kobold, ACM, Franssen, CF, et al.. Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol 2014;9:1553–62. https://doi.org/10.2215/cjn.08690813.Search in Google Scholar PubMed PubMed Central
17. Gattone, VH, Wang, X, Harris, PC, Torres, VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003;9:1323–6. https://doi.org/10.1038/nm935.Search in Google Scholar PubMed
18. Meijer, E, Bakker, SJ, van der Jagt, EJ, Navis, G, de Jong, PE, Struck, J, et al.. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:361–8. https://doi.org/10.2215/cjn.04560510.Search in Google Scholar
19. Zittema, D, Boertien, WE, van Beek, AP, Dullaart, RP, Franssen, CF, de Jong, PE, et al.. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clin J Am Soc Nephrol 2012;7:906–13. https://doi.org/10.2215/cjn.11311111.Search in Google Scholar PubMed
20. Nakajima, A, Lu, Y, Kawano, H, Horie, S, Muto, S. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD). Clin Exp Nephrol 2015;19:1199–205. https://doi.org/10.1007/s10157-015-1101-7.Search in Google Scholar PubMed
21. Johnston, C. Radioimmunoassay for plasma antidiuretic hormone. J Endocrinol 1972;52:69–78. https://doi.org/10.1677/joe.0.0520069.Search in Google Scholar PubMed
22. Beardwell, C. Radioimmunoassay of arginine vasopressin in human plasma. J Clin Endocrinol Metabol 1971;33:254–60. https://doi.org/10.1210/jcem-33-2-254.Search in Google Scholar PubMed
23. Robertson, GL, Mahr, EA, Athar, S, Sinha, T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Investig 1973;52:2340–52. https://doi.org/10.1172/jci107423.Search in Google Scholar
24. Miller, M, Moses, AM. Urinary antidiuretic hormone in polyuric disorders and in inappropriate ADH syndrome. Ann Intern Med 1972;77:715–21. https://doi.org/10.7326/0003-4819-77-5-715.Search in Google Scholar PubMed
25. Sollanek, KJ, Staab, JS, Kenefick, RW, Cheuvront, SN. Biological variation of arginine vasopressin. Eur J Appl Physiol 2020;120:635–42. https://doi.org/10.1007/s00421-020-04303-x.Search in Google Scholar PubMed
26. Miller, M, Moses, AM. Radioimmunoassay of urinary antidiuretic hormone in man: response to water load and dehydration in normal subjects. J Clin Endocrinol Metabol 1972;34:537–45. https://doi.org/10.1210/jcem-34-3-537.Search in Google Scholar PubMed
27. Shimura, N, Arisaka, O. Urinary arginine vasopressin in asthma: consideration of fluid therapy. Pediatr Int 1990;32:197–200. https://doi.org/10.1111/j.1442-200x.1990.tb00810.x.Search in Google Scholar PubMed
28. Puri, V. Urinary anti diuretic hormone level in essential hypertension. Pharmacol Res Commun 1987;19:53–8. https://doi.org/10.1016/0031-6989(87)90032-4.Search in Google Scholar PubMed
© 2025 Walter de Gruyter GmbH, Berlin/Boston
